Yuan Ligong, Li Feng, Wang Shuaibo, Yi Hang, Li Fang, Mao Yousheng
Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Front Oncol. 2021 Aug 2;11:719812. doi: 10.3389/fonc.2021.719812. eCollection 2021.
Lung adenocarcinoma (LUAD) is the most common type of lung cancer and is a severe threat to human health. Although many therapies have been applied to LUAD, the long-term survival rate of patients remains unsatisfactory. We aim to find reliable immune microenvironment-related lncRNA biomarkers to improve LUAD prognosis.
ESTIMATE analysis was performed to evaluate the degree of immune infiltration of each patient in TAGA LUAD cohort. Correlation analysis was used to identify the immune microenvironment-related lncRNAs. Univariate cox regression analysis, LASSO analysis, and Kaplan Meier analysis were used to construct and validate the prognostic model based on microenvironment-related lncRNAs.
We obtained 1,178 immune microenvironment-related lncRNAs after correlation analysis. One hundred and eighty of them are independent prognostic lncRNAs. Sixteen key lncRNAs were selected by LASSO method. This lncRNA-based model successfully predicted patients' prognosis in validation cohort, and the risk score was related to pathological stage. Besides, we also found that TP53 had the highest frequency mutation in LUAD, and the mutation of TP53 in the high-risk group, which was identified by our survival model, has a poor prognosis. lncRNA-mRNA co-expression network further suggested that these lncRNAs play a vital role in the prognosis of LUAD.
Here, we filtered 16 key lncRNAs, which could predict the survival of LUAD and may be potential biomarkers and therapeutic targets.
肺腺癌(LUAD)是肺癌最常见的类型,对人类健康构成严重威胁。尽管已将多种疗法应用于肺腺癌,但患者的长期生存率仍不尽人意。我们旨在寻找可靠的免疫微环境相关lncRNA生物标志物以改善肺腺癌的预后。
对TAGA肺腺癌队列中的每位患者进行ESTIMATE分析以评估免疫浸润程度。采用相关性分析来鉴定免疫微环境相关的lncRNA。使用单变量cox回归分析、LASSO分析和Kaplan Meier分析基于微环境相关lncRNA构建并验证预后模型。
相关性分析后我们获得了1178个免疫微环境相关的lncRNA。其中180个是独立的预后lncRNA。通过LASSO方法选择了16个关键lncRNA。这个基于lncRNA的模型在验证队列中成功预测了患者的预后,并且风险评分与病理分期相关。此外,我们还发现TP53在肺腺癌中的突变频率最高,并且我们的生存模型鉴定出的高危组中TP53的突变预后较差。lncRNA-mRNA共表达网络进一步表明这些lncRNA在肺腺癌的预后中起重要作用。
在此,我们筛选出16个关键lncRNA,它们可以预测肺腺癌的生存情况,可能是潜在的生物标志物和治疗靶点。